Role of a Pharmacist in Postdischarge Care for Patients With Kidney Disease: A Scoping Review.

Autor:	Manis MM; Department of Pharmacy Practice, McWhorter School of Pharmacy, Samford University, Birmingham, AL, USA.; Division of Nephrology, Department of Medicine, The University of Alabama at Birmingham, Birmingham, AL, USA., Skelley JW; Department of Pharmacy Practice, McWhorter School of Pharmacy, Samford University, Birmingham, AL, USA., Read JB; Department of Pharmacy Practice, McWhorter School of Pharmacy, Samford University, Birmingham, AL, USA., Maxson R; Department of Pharmacy Practice, Harrison College of Pharmacy, Auburn University, Auburn, AL, USA., O'Hagan E; Department of Libraries, The University of Alabama at Birmingham, Birmingham, AL, USA., Wallace JL; Department of Pharmacy Practice, College of Pharmacy, Lipscomb University, Nashville, TN, USA.; Department of Pharmacy, Vanderbilt University Medical Center, Nashville, TN, USA., Siew ED; Division of Nephrology and Hypertension, Vanderbilt University Medical Center, Nashville, TN, USA.; Tennessee Valley Health Systems (TVHS), Nashville Veterans Affairs Medical Center, Nashville, TN, USA., Barreto EF; Department of Pharmacy, Mayo Clinic, Rochester, MN, USA., Silver SA; Division of Nephrology, Kingston Health Sciences Center, Queen's University, Kingston, ON, Canada., Kane-Gill SL; Department of Pharmacy and Therapeutics, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA, USA., Neyra JA; Division of Nephrology, Department of Medicine, The University of Alabama at Birmingham, Birmingham, AL, USA.
Jazyk:	angličtina
Zdroj:	The Annals of pharmacotherapy [Ann Pharmacother] 2024 Apr 02, pp. 10600280241240409. Date of Electronic Publication: 2024 Apr 02.
DOI:	10.1177/10600280241240409
Abstrakt:	Objective: The objective was to explore and describe the role of pharmacists in providing postdischarge care to patients with kidney disease. Data Sources: PubMed, Embase (Elsevier), CINAHL (Ebscohost), Web of Science Core Collection, and Scopus were searched on January 30, 2023. Publication date limits were not included. Search terms were identified based on 3 concepts: kidney disease, pharmacy services, and patient discharge. Experimental, quasi-experimental, observational, and qualitative studies, or study protocols, describing the pharmacist's role in providing postdischarge care for patients with kidney disease, excluding kidney transplant recipients, were eligible. Study Selection and Data Extraction: Six unique interventions were described in 10 studies meeting inclusion criteria. Data Synthesis: Four interventions targeted patients with acute kidney injury (AKI) during hospitalization and 2 evaluated patients with pre-existing chronic kidney disease. Pharmacists were a multidisciplinary care team (MDCT) member in 5 interventions and were the sole provider in 1. Roles commonly identified include medication review, medication reconciliation, medication action plan formation, kidney function assessment, drug dose adjustments, and disease education. Some studies showed improvements in diagnostic coding, laboratory monitoring, medication therapy problem (MTP) resolution, and patient education; prevention of hospital readmission was inconsistent. Limitations include lack of standardized reporting of kidney disease, transitions of care processes, and differences in outcomes evaluated. Relevance to Patient Care and Clinical Practice: This review identifies potential roles of a pharmacist as part of a postdischarge MDCT for patients with varying degrees of kidney disease. Conclusions: The pharmacist's role in providing postdischarge care to patients with kidney disease is inconsistent. Multidisciplinary care teams including a pharmacist provided consistent identification and resolution of MTPs, improved patient education, and increased self-awareness of diagnosis. Competing Interests: Declaration of Conflicting InterestsThe authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: MMM, JWS, JBR, JLW, RM, and EO have nothing to disclose. EFB is supported by a grant from the National Institute of Allergy and Infectious Diseases (K23AI143882). The funding source had no role in this manuscript and its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH. Consulting relationship with Wolters-Kluwer. SKG is supported by grants from the National Institute of Diabetes and Digestive and Kidney Diseases R01DK121730 and U01DK130010, the National Center for Complementary and Integrative Health U54AT008909, and the Jewish Healthcare Foundation. SKG holds an executive position in the Society of Critical Care Medicine. The content of this manuscript is solely the responsibility of the author and does not represent the official views of the Society of Critical Care Medicine. EDS Personal fees for service on the editorial board for the Clinical Journal of the American Society of Nephrology, royalties as an author for UptoDate, and consulting agreement with Novartis Pharmaceutics for DSMB service. SAS discloses the following speaking fees from Baxter Canada, consulting from AstraZeneca, and honorarium from Otsuka and Novo Nordisk. JAN is supported by grants from NIDDK (R01DK128208, R01DK133539, U01DK12998, and U54DK137307).
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu